Class Action Lawsuit Against Organon & Co. – Key Details for Investors

Investor Reminder: Class Action Lawsuit Filed Against Organon & Co.

On June 4, 2025, Berger Montague PC disclosed important information regarding a securities class action lawsuit against Organon & Co. (NYSE: OGN). This lawsuit targets purchasers of Organon securities from October 31, 2024, through April 30, 2025, which constitutes the specified Class Period. Investors within this timeframe are urged to consider their options, especially if they are looking to be recognized as lead plaintiff representatives in the ongoing litigation.

Important Deadlines for Investors

It is crucial for investors who acquired Organon securities during the Class Period to note that the deadline for applying as a lead plaintiff is set for July 22, 2025. If you're interested in learning more about your rights and potential actions, Berger Montague provides information through their official communication channels.

Overview of Organon & Its Recent Developments

Based in Jersey City, New Jersey, Organon is a healthcare firm primarily focused on advancing women’s health. A notable event within the company was its acquisition of Dermavant, a biopharmaceutical entity dedicated to treating dermatological conditions, for a significant sum of $1.2 billion in October 2024. Despite this ambitious move, the acquisition increased the company's debt considerably.

In its communication with investors, Organon assured that it would prioritize maintaining its dividend payouts. This assurance positioned its dividend as the company's essential capital allocation priority.

Disclosure of Dividend Changes

However, on May 1, 2025, the situation took an unexpected turn when the company announced a dramatic reduction of its dividend payout from $0.28 to $0.02 per share. This change raised concerns among investors as the management indicated a shift in its capital allocation priorities to focus on lowering debt levels instead of distributing capital back to shareholders.

Following this announcement, Organon’s stock witnessed a remarkable decline of 27%, plummeting from $12.93 per share on April 30 to a closing price of $9.45 on May 1. This steep drop reflects investor concerns regarding the company's financial health and future strategies.

Call to Investors and Legal Implications

Berger Montague emphasizes that individuals participating in the lawsuit do not need to communicate with the law firm or become lead plaintiffs to be eligible for any recovery resulting from the lawsuit. Any member of the class can express their desire to act as lead plaintiff through the representation of their choice or opt to remain inactive in the proceedings. The law firm has extensive experience in securities class action cases and has represented various investors for over 50 years.

Investors needing clarification or wishing to discuss their options can reach out to Senior Counsel Andrew Abramowitz at (215) 875-3015 or via email at [email protected]. Alternatively, inquiries can also be directed to Peter Hamner at [email protected].

This class action serves as a crucial reminder for investors regarding their rights and the importance of vigilance in their investment activities, particularly in light of significant corporate changes within a company. Stakeholders are encouraged to stay informed and actively participate in protecting their investments.